Biomarker points to Alzheimer's risk

March 11, 2014 by Mark Michaud
Biomarker points to Alzheimer’s risk

(Medical Xpress)—A study involving Rochester-area seniors has yielded the first accurate blood test that can predict who is at risk for developing Alzheimer's disease. This discovery – which appears today in the journal Nature Medicine – could be the key to unlocking a new generation of treatments that seek to head off the disease before neurological damage becomes irreversible.

The biomarker – which consists of 10 specific lipids found in – predicted with greater than 90 percent accuracy which individuals would go on to develop Alzheimer's disease or a precursor condition known as amnestic (aMCI). The cost of the simple required to detect these lipids is a fraction of other techniques and, unlike alternatives, it identifies risk early in the disease process before cognitive symptoms appears.

"The ability to identify individuals who are at risk of developing Alzheimer's before the clinical manifestation of has long been a Holy Grail of the neuromedicine community," said Mark Mapstone, Ph.D., a neuropsychologist with the University of Rochester School of Medicine and Dentistry and lead author of the study. "Current efforts to develop a treatment for this disease are coming up short because they are probably being used too late. Biomarkers that can allow us to intervene early in the course of the disease could be a game-changer."

Alzheimer's research is at an impasse with many once promising experimental therapies failing in late stage clinical trials. These setbacks have led all but a few major pharmaceutical companies to pull back from their research and development in the disease.

The absence of an effective treatment for Alzheimer's, and the dwindling options in the drug development pipeline, mean that the nation – and the world – are woefully unprepared for the coming "Silver Tsunami" of aging baby boomers who will develop the disease in the coming years. By 2050, an estimated 14 million Americans will have Alzheimer's, consuming an estimated $1.2 trillion in health care costs per year.

There is an emerging scientific consensus that once the cognitive symptoms of the Alzheimer's have emerged, it may be too late to slow or reverse the caused by the disease. Researchers speculate that if treatments could be initiated early in the disease cycle, they may stand more of a chance of being effective. In fact, many of the same experimental treatments that have failed in recent clinical studies may ultimately prove to be successful if they are given to patients sooner. The challenge is there currently exists no way to identify which people are at risk of developing Alzheimer's.

There are several screening methods that can detect Alzheimer's disease. These include spinal taps which measure the presence of the proteins beta amyloid and tau and advanced imaging systems such as MRIs, PET scans, and functional MRIs that spot changes in the brain. But these techniques have significant limitations. First, they have only been shown to be effective in confirming the diagnosing of the diseases after the have surfaced. And second, the high cost associated with these technologies is a significant barrier to widespread use in clinical practice.

The Rochester Aging Study, which was launched in 2007, is a community-wide collaboration that involves physicians and researchers from the University of Rochester School of Medicine and Dentistry, Unity Health, and Rochester General Health System.

In total, 425 seniors from the Rochester area participated in the study. The volunteers underwent a comprehensive cognitive assessment and a blood draw once a year over a five-year period. An additional 100 individuals from Irvine, CA were enrolled in the study.

Researchers at the University of Rochester and Georgetown University used a technique called mass spectrometry to screen for lipid levels in blood plasma. Lipids are a class of naturally occurring molecules found in the body that play a role in energy storage, signaling, and form the structural components of cell membranes. The scientists identified 10 specific lipids that, if present in lower than normal levels, could predict with more than 90 percent accuracy whether an individual would go on to develop either Alzheimer's or aMCI.

The scientists are not entirely sure why this particular set of lipids is indicative of Alzheimer's. All ten represent a class of lipids called phospholipids, molecules that are important cellular building blocks. The researchers speculate that the lower lipid levels could be an early indication that the brain cells lost in the disease are beginning to lose their integrity and break down.

Once commercialized, a blood test required to detect these lipids would likely cost less than $200 – compared to thousands of dollars for a spinal tap or MRI – and could be ordered as a part of a routine exam by an individual's primary care physician.

"Having a tool that is able to identify, with a high degree of accuracy and at a low cost, which individuals will convert to Alzheimer's could transform how we care for this devastating disease," said Mapstone.

Explore further: Blood test identifies those at-risk for cognitive decline, Alzheimer's within three years

Related Stories

Blood test identifies those at-risk for cognitive decline, Alzheimer's within three years

March 9, 2014
Researchers have discovered and validated a blood test that can predict with greater than 90 percent accuracy if a healthy person will develop mild cognitive impairment or Alzheimer's disease within three years.

Blood biomarker could mark severe cognitive decline, quicker progression among Parkinson's patients

September 18, 2013
A genetic mutation, known as GBA, that leads to early onset of Parkinson's disease and severe cognitive impairment (in about 4 to 7 percent of all patients with the disease) also alters how specific lipids, ceramides and ...

Plaques detected in brain scans forecast cognitive impairment

March 11, 2014
Brain imaging using radioactive dye can detect early evidence of Alzheimer's disease that may predict future cognitive decline among adults with mild or no cognitive impairment, according to a 36-month follow-up study led ...

Inherited Alzheimer's damage greater decades before symptoms appear

March 7, 2014
(Medical Xpress)—The progression of Alzheimer's may slow once symptoms appear and do significant damage , according to a study investigating an inherited form of the disease.

New approach could lead to blood test to diagnose Alzheimer's in earliest stage

May 29, 2013
Blood offers promise as a way to detect Alzheimer's disease at its earliest onset, Mayo Clinic researchers say. They envision a test that would detect distinct metabolic signatures in blood plasma that are synonymous with ...

Scientists spot early signs of Alzheimer's disease

July 9, 2013
Early signs of Alzheimer's disease can be detected years before diagnosis, according to researchers at Birmingham City University.

Recommended for you

Artificial intelligence predicts dementia before onset of symptoms

August 22, 2017
Imagine if doctors could determine, many years in advance, who is likely to develop dementia. Such prognostic capabilities would give patients and their families time to plan and manage treatment and care. Thanks to artificial ...

Chronic stress induces fatal organ dysfunctions via a new neural circuit

August 22, 2017
Hokkaido University researchers revealed that fatal gut failure in a multiple sclerosis (MS) mouse model under chronic stress is caused by a newly discovered nerve pathway. The findings could provide a new therapeutic strategy ...

Noninvasive eye scan could detect key signs of Alzheimer's years before patients show symptoms

August 17, 2017
Cedars-Sinai neuroscience investigators have found that Alzheimer's disease affects the retina—the back of the eye—similarly to the way it affects the brain. The study also revealed that an investigational, noninvasive ...

Could olfactory loss point to Alzheimer's disease?

August 16, 2017
By the time you start losing your memory, it's almost too late. That's because the damage to your brain associated with Alzheimer's disease (AD) may already have been going on for as long as twenty years. Which is why there ...

New Machine Learning program shows promise for early Alzheimer's diagnosis

August 15, 2017
A new machine learning program developed by researchers at Case Western Reserve University appears to outperform other methods for diagnosing Alzheimer's disease before symptoms begin to interfere with every day living, initial ...

Brain scan study adds to evidence that lower brain serotonin levels are linked to dementia

August 14, 2017
In a study looking at brain scans of people with mild loss of thought and memory ability, Johns Hopkins researchers report evidence of lower levels of the serotonin transporter—a natural brain chemical that regulates mood, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.